Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma

被引:0
|
作者
Yamamoto, S
Kijima, H
Hara, T
Chino, O
Shimada, H
Tanaka, M
Inokuchi, S
Makuuchi, H
机构
[1] Hirosaki Univ, Sch Med, Dept Pathol, Hirosaki, Aomori 0368562, Japan
[2] Tokai Univ, Sch Med, Dept Surg, Isehara, Kanagawa 2591193, Japan
[3] Tokai Univ, Sch Med, Dept Crit Care & Emergency Med, Isehara, Kanagawa 2591193, Japan
关键词
esophageal carcinoma; Barrett's adenocarcinoma; mucin; Ki-67;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Barrett's esophagus is a premalignant condition associated with gastroesophageal reflux disease, and consists of mucosa with a metaplastic columnar epithelium (specialized columnar epithelium). In this study, we examined the expression of mucin and the Ki-67 labeling index (LI) in 15 cases of esophageal Barrett's adenocarcinoma, and clarified the significance of incomplete intestinal metaplasia of Barrett's mucosa as a premalignant lesion. Gastric mucin (MUC5AC, HGM, and/or MUC6) was detected in 93.3% of the adenocarcinomas, while MUC2 and CD10 (markers of intestinal phenotypes) were detected in 73.3% and 46.2%, respectively. The Ki-67 LI was 34.1% in Barrett's adenocarcinoma. In all cases, gastric mucin was found in the non-neoplastic Barrett's mucosa around the adenocarcinoma. MUC2 was detected in 86.7% of proximal non-neoplastic mucosa and 100% of distal non-neoplastic mucosa, while CD10 was found in 20.0% of proximal non-neoplastic mucosa and 40.0% of distal non-neoplastic mucosa of Barrett's adenocarcinoma. In conclusion, Barrett's esophageal mucosa with intestinal metaplasia and a high Ki-67 LI is suggested to be more important as a premalignant lesion, and predominantly found in the proximal rather than distal region of Barrett's esophagus.
引用
收藏
页码:375 / 380
页数:6
相关论文
共 50 条
  • [21] Focus on Barrett's esophagus and esophageal adenocarcinoma
    Paulson, TG
    Reid, BJ
    [J]. CANCER CELL, 2004, 6 (01) : 11 - 16
  • [22] Familial Barrett’s Esophagus and Esophageal Adenocarcinoma
    Joel Gabre
    Amitabh Chak
    Anil Rustgi
    [J]. Current Treatment Options in Gastroenterology, 2020, 18 (4) : 616 - 622
  • [23] Barrett’s Esophageal Adenocarcinoma with CREST Syndrome
    Tomohiro Kunishige
    Sohei Matsumoto
    Kohei Wakatsuki
    Kazuhiro Migita
    Masahiro Ito
    Hiroshi Nakade
    Mitsuhiro Nakatani
    Mutsuko Kitano
    Kohei Morita
    Chiho Obayashi
    Yoshiyuki Nakajima
    [J]. Esophagus, 2017, 14 : 262 - 267
  • [24] Recurring Translocations in Barrett's Esophageal Adenocarcinoma
    Bajpai, Manisha
    Panda, Anshuman
    Birudaraju, Kristen
    Van Gurp, James
    Chak, Amitabh
    Das, Kiron M.
    Javidian, Parisa
    Aviv, Hana
    [J]. FRONTIERS IN GENETICS, 2021, 12
  • [25] Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers
    Grady, William M.
    Yu, Ming
    Markowitz, Sanford D.
    Chak, Amitabh
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (12) : 2486 - 2494
  • [26] Diagnosis and treatment of Barrett’s esophageal adenocarcinoma
    Alan J. Cameron
    [J]. Esophagus, 2003, 1 (1) : 31 - 35
  • [27] Biomarkers of esophageal adenocarcinoma and Barrett's esophagus
    McManus, DT
    Olaru, A
    Meltzer, SJ
    [J]. CANCER RESEARCH, 2004, 64 (05) : 1561 - 1569
  • [28] MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma
    Kan, Takatsugu
    Meltzer, Stephen J.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (06) : 727 - 732
  • [29] Barrett's Esophageal Adenocarcinoma with CREST Syndrome
    Kunishige, Tomohiro
    Matsumoto, Sohei
    Wakatsuki, Kohei
    Migita, Kazuhiro
    Ito, Masahiro
    Nakade, Hiroshi
    Nakatani, Mitsuhiro
    Kitano, Mutsuko
    Morita, Kohei
    Obayashi, Chiho
    Nakajima, Yoshiyuki
    [J]. ESOPHAGUS, 2017, 14 (03) : 262 - 267
  • [30] Advances in Barrett's esophagus and esophageal adenocarcinoma
    Shaheen, NJ
    [J]. GASTROENTEROLOGY, 2005, 128 (06) : 1554 - 1566